The best regulatory affairs software is the product - or combination of products - that produces the records your team needs to control. A submission publisher, a registration database, and a regulatory-intelligence service solve different problems, even when their websites all describe an end-to-end platform.
Assyro is our first recommendation to evaluate for an eligible FDA eCTD v4.0 workflow involving authoring, review, validation, and submission. It is not a current v3.2.2 option, and its document-management capability should not be mistaken for demonstrated full registration-management functionality. If those are mandatory requirements, follow the relevant alternatives below.
Quick Answer
Start with the required output. Evaluate Assyro for an eligible FDA v4.0 workflow; established publishing products for dossier production and lifecycle work; a RIM suite for registrations and correspondence; a document-centered platform for publishing handoffs; and a regulatory-intelligence product for external requirements research. Require every candidate to pass your mandatory gates before comparing preferences.
Disclosure and method: Assyro publishes this guide, and its first position is our editorial recommendation. This is a documentary shortlist based on official product material checked on October 6, 2026, plus Assyro's current product status. We have not conducted a comparative hands-on benchmark. The scenarios and worksheet are original illustrative purchasing exercises, not customer results or a complete market ranking.
A shortlist organized by the purchase you are making
The links in the product column identify the official evidence behind each documented role. They establish a reason to evaluate, not proof that your intended configuration has passed acceptance.
| Product | Documented role worth evaluating | Decisive purchasing boundary |
|---|---|---|
| Assyro | FDA v4.0 authoring, review, validation, and submission; document management | No v3.2.2 today; EMA is roadmap; full RIM scope requires separate confirmation |
| Veeva RIM | Connected registrations, submissions, publishing, and archive applications | Specify the applications and data migration included |
| ArisGlobal LifeSphere Regulatory | Modular regulatory data, documents, submissions, labeling, and analytics | Define which modules and shared records the contract covers |
| IQVIA SmartSolve RIM | Registrations and regulatory operations connected with quality workflows | Confirm the current platform and migration from any older IQVIA deployment |
| Ennov Regulatory | Regulatory documents, Ennov RIM, and Ennov Dossier publishing | Choose the named applications rather than assuming the suite label includes all of them |
| LORENZ docuBridge | Submission compilation, publishing, import, and lifecycle review | ONE, TWO, and FIVE have different user, deployment, and module scopes |
| EXTEDOpulse Submission Publishing | Dossier assembly, publishing, technical validation, and lifecycle management | Identify the contracted build and connections to other EXTEDOpulse hubs |
| Freyr SUBMIT PRO | Submission preparation with validator, viewer, and cloning functions | Separate the software configuration from any contracted publishing service |
| Kivo RIM | Controlled content, submission assembly, correspondence, and publishing handoff | Its documented workflow retains an internal or external publishing group |
| Cortellis Regulatory Intelligence | Regulatory source documents, summaries, reports, and comparison tables | Assess the subscribed content and how research becomes an owned internal action |
Choose among five workflow categories
Retain this category map when building your shortlist. A vendor can span several rows, but a feature in one row does not establish another. Regulatory information management concerns the records and relationships behind regulatory work; eCTD concerns the structured electronic submission. Keeping those concepts separate makes the comparison more useful.
| Category | Required output | Boundary to keep visible |
|---|---|---|
| Regulatory information management | Product/application records, registration status, correspondence, and owned commitments | A document folder alone does not establish the relationships or current status |
| Publishing and submission operations | Assembled dossier, technical reports, lifecycle history, and agreed delivery records | Publishing, technical validation, and gateway transmission are separate operations |
| Content preparation and review | Controlled source documents, review decisions, and accepted writing outputs | An AI-generated draft is not evidence of approved content |
| Submission planning and tracking | Content plan, responsible owners, dates, dependencies, and handoff package | A progress dashboard does not create or transmit the submission |
| Regulatory intelligence | Relevant official sources, change context, and research supporting an applicability decision | An alert is not an approved conclusion about your product |
Use the specialist RIM guide, publishing comparison, submission-software guide, and intelligence comparison once you know which category you are buying. This guide helps choose the category and shortlist; those pages go deeper into their respective workflows.
Product assessments and the demonstrations that matter
1. Assyro: start here for an eligible FDA v4.0 workflow
Assyro's current supported FDA offering covers eCTD authoring, review, validation, and submission, with document management also shipped. That makes it a candidate when the buying task combines preparing content and progressing an eligible FDA package. The relevant starting points are regulatory writing and document management.
The boundaries change the shortlist. eCTD v3.2.2 is not supported today. EMA is on the roadmap. Health Canada is live, but no customer is using that capability yet; do not treat it as customer-proven filing evidence. Full registration management, IDMP, and regulatory-intelligence scope are not established by the shipped document or FDA submission capabilities.
For a demo, bring one approved source, one later draft, and a short content plan for your application type. Ask the team to agree which operations are supported in the current product, then show the selected source, review output, validation report, and submission handoff where in scope. Keep an evidence record of what actually happens; none of these proposed demonstration results is claimed here.
The purchasing advantage to investigate is whether the supported workflow reduces your own coordination burden. It is not an assumed accuracy or time-saving advantage over competitors. If your must-have is maintaining a v3.2.2 application or replacing a registration database, resolve that boundary before spending time on a broader demo.
2. Veeva RIM: a named application model for connected regulatory records
Veeva identifies four RIM applications: Registrations, Submissions, Submissions Publishing, and Submissions Archive. Its official description distinguishes registration tracking, content planning and review, publishing, and the repository of submitted applications and correspondence. This gives buyers a clearer procurement starting point than an undifferentiated suite label. See Veeva's application overview.
Evaluate it when the objective is to connect application data with controlled content and submitted history across teams. Ask the proposal to identify the applications being licensed, their rollout order, and who owns the underlying product and registration data. Shared platform branding does not remove the work of mapping inconsistent legacy records.
A useful demonstration starts with one registration and follows it to an authority letter, a commitment, its responsible owner, and the relevant submitted document. Then ask what changes when the owner leaves or a document is superseded. Retain the record identifiers, not just a screenshot of the dashboard.
The tradeoff to assess is the value of connected records against the scope of the implementation you actually need. Do not assume a clinical-stage company needs every application, or that a large company can skip testing a specific publishing configuration.
3. ArisGlobal LifeSphere Regulatory: evaluate the module boundaries
ArisGlobal describes LifeSphere Regulatory as a modular ecosystem with RIM, Product Compliance, Documents, Submissions, Labeling, and Analytics. These are distinct operational areas, including product-data work and labeling processes that extend beyond compiling a dossier. The evidence is the current LifeSphere Regulatory product map.
This is a relevant candidate when regulatory records and processes need to connect across more than the immediate filing workflow. Ask which shared identifiers link a product, its documents, and its activities, and which modules must be present for the promised workflow. An attractive suite-wide demonstration may include applications outside the proposed contract.
Use a labeling-change example: identify a product, record the proposed change, identify affected activities, and assign review responsibilities. Ask the demonstrator to distinguish configured behavior from manual steps and newly proposed customization. No result from that exercise has been measured for this guide.
The decision is whether the named combination fits your operating model. Current marketing also discusses AI; treat each AI task as a separate intended-use question rather than evidence that the whole regulatory lifecycle can operate without accountable review.
4. IQVIA SmartSolve RIM: examine the quality-to-regulatory connection
IQVIA's current offering is presented as SmartSolve RIM. Its product page describes registration management, authority interactions, document management, submission/publishing management, and connections between quality change plans and registrations. Older RIM Smart material remains online; confirm the platform and version in your proposal rather than assuming old and current descriptions are interchangeable. See IQVIA SmartSolve RIM.
The distinctive evaluation question is whether a quality event can become a traceable regulatory assessment in your configured system. Supply a fictional change affecting one product and ask the vendor to show its linked registrations, proposed activities, reviewer, and closure evidence. An automatically generated impact list still needs a defined approval process.
IQVIA documents migration assistance on the same page. Ask for a migration inventory and acceptance plan covering correspondence, open commitments, attachments, and relationships - not only row counts. If you already use an IQVIA product, establish exactly which records and controls carry forward.
Do not base this decision on an old fact sheet's broad format claims. Put your current region, format, application type, and required operation in the demonstration scope.
5. Ennov Regulatory: separate documents, registrations, and publishing
Ennov's suite identifies Ennov Regulatory Documents, Ennov RIM, and Ennov Dossier separately. The product descriptions distinguish controlled regulatory content, product/registration data, and submission publishing. Ennov also lists a separate IDMP offering. These distinctions help a buyer specify what the initial implementation must contain. See Ennov's regulatory suite.
Evaluate this combination when you want connected document and regulatory-data workflows but need to choose the scope application by application. Ask how an approved source document becomes part of a dossier and remains associated with the relevant regulatory activity. Then replace the approved source with a revision and inspect what happens to the prepared and previously published records.
The implementation question is not simply whether the applications connect. It is which system owns each field, how existing document versions are migrated, and how users recognize an unresolved discrepancy. Specify those responsibilities before choosing a rollout sequence.
A publishing requirement should name Ennov Dossier and the required regional/version configuration. A registration-data requirement should identify the RIM records and reports. Avoid treating a purchase of one as evidence that every capability in the suite is included.
6. LORENZ docuBridge: select the publishing edition deliberately
LORENZ describes docuBridge as a system for compiling, publishing, importing, and reviewing submissions. Its ONE, TWO, and FIVE editions differ in user model, deployment, and available modules: ONE is a single-user workstation offering, while TWO and FIVE address multi-user publishing with different configuration scope. The official edition comparison also distinguishes commercial models and optional modules.
This makes docuBridge a candidate when the problem is submission production and lifecycle work. Your purchase specification should say how many people work on the same application, which regions and formats they need, and whether the environment must connect to an existing content repository.
For an existing application, provide a permitted historical submission and ask for an import, a current view, and preparation of the next lifecycle change. Verify the documents, links, metadata, and prior history you need to retain. This is a proposed acceptance task, not a claim that every edition has passed it.
The practical tradeoff is edition fit: a smaller publishing footprint and a configurable multi-user environment are different purchases. Do not let a demonstration of an expanded configuration stand in for the edition you will license.
7. EXTEDOpulse Submission Publishing: clarify the current product configuration
EXTEDO's current product-information PDF is headed EXTEDOpulse Submission Publishing, even though the download filename still contains eCTDmanager. It describes dossier assembly, publishing, built-in technical validation, and lifecycle management, available standalone or connected to other EXTEDOpulse hubs. The current product-information document is the basis for this assessment.
For buyers familiar with eCTDmanager, identify the exact product name, release, hosting arrangement, and licensed connections in the proposal. This avoids comparing a current integrated demonstration with an older standalone deployment as though they were the same configuration.
Ask for an approved content plan to enter publishing, a revised source to be identified, and the resulting package to be reviewed with the applicable technical report. Where another EXTEDOpulse hub owns master data or planning, record that dependency and its license cost.
The document discusses eCTD v3 and v4, but generic version support does not establish the correct authority-specific route for your application. Require the installed specification/rule-set versions and the output for your actual use case. FDA's current transition boundary remains a separate gate below.
8. Freyr SUBMIT PRO: distinguish the tool from who operates it
Freyr's current SUBMIT PRO page describes submission-management software with a validator, viewer, sequence/application cloning, and metadata functions. Its official site now presents the product within the freya fusion web presence. Use the current SUBMIT PRO page to identify the offer rather than treating multiple Freyr websites as separate products.
It belongs on a publishing shortlist when those operations match the team's workload. If the proposal includes publishing services, request two deliverable lists: what the software enables your users to do, and what the service team will perform. Include review rounds, corrections, package ownership, and after-hours responsibilities.
Demonstrate a repeat submission using a previously supplied application, then inspect the cloned metadata and changed documents. The question is whether reuse preserves the correct context, not whether the demo generates output quickly. Require current authority/version evidence without importing marketing performance percentages into your business case.
This separation is especially useful when deciding between building an internal publishing capability and buying an operated workflow. Compare the options using the same retained records and sponsor responsibilities.
9. Kivo RIM: controlled content with a publishing handoff
Kivo's RIM documentation describes document control, submission assembly, project activities, correspondence, commitments, and submitted eCTD viewing. Its publishing FAQ explicitly describes preparing content and handing it to an internal or external publishing group. That is a meaningful workflow boundary, not merely a generic “lightweight tracking” label. See Kivo RIM.
Evaluate it when the team wants to control source content and submission readiness while retaining a publishing partner or internal production system. The interface between those teams becomes a central acceptance test.
Ask for a content plan containing approved and unfinished documents, an export, and a second export after one approved document changes. The publisher should be able to identify the approved files and changes from the retained handoff evidence. Then check how the final submitted package and correspondence return to the sponsor's records.
If your requirement is for one product to perform publishing itself, the documented handoff workflow does not satisfy that requirement. If retaining a publisher is intentional, it may fit the operating model. Do not count external publishing fees or coordination work as included merely because the software prepares an export.
10. Cortellis Regulatory Intelligence: buy the research coverage you need
Clarivate's Cortellis Regulatory Intelligence materials describe source documents, regulatory summaries, intelligence reports, and cross-country comparison tables. The current product material also presents assisted search and document comparison. These are research functions to evaluate against your therapeutic area, product type, and markets. See Cortellis Regulatory Intelligence.
Give the supplier a known regulatory question and request the underlying official source, its version/date, and the relevant comparison with an earlier version. Ask which content collection and access rights the demonstration uses. A count of documents or countries cannot answer whether the specific requirement you need is covered.
Keep the next step visible: who assesses applicability, where the decision is retained, and which system assigns any resulting work. Research access alone does not establish registration management or publishing capability.
Cortellis is therefore a candidate for an intelligence requirement in the stack, not an interchangeable substitute for the publishers above. Use the separate intelligence guide for a deeper alert-to-action evaluation.
Adjacent options depend on your product and process
Medical-device teams should explicitly investigate device-focused systems. Rimsys describes connected device regulatory information, product data, approvals, submissions, and UDI. RegDesk currently positions its RIM around medical-device manufacturers and regulatory intelligence. Those are reasons to evaluate them for device workflows, not evidence of equivalent pharmaceutical application support.
If the immediate bottleneck is quality events, training, or controlled quality documents, MasterControl's QMS offering is relevant. Keep quality-process selection distinct from a publisher or registration-database purchase; the CAPA comparison addresses that neighboring task.
Company size alone should not select among these categories. A small sponsor with a complex existing submission history can have stricter lifecycle needs than a larger team preparing a new application.
Three buyer situations that produce different shortlists
These are fictional scenarios. They illustrate decisions, not vendor test outcomes.
A first eligible FDA filing
Situation: A sponsor is preparing a new application and has confirmed that its intended v4.0 route is eligible. Its immediate need is controlled preparation and a supported submission workflow, rather than a global registration database.
Required output: An approved content set, agreed technical validation evidence, submission-ready output, and defined transmission/receipt responsibilities.
Choice: Start with Assyro for the supported FDA v4.0 scope. Compare a configured publishing option if the organization needs a different operating model. Retain existing scientific review and source approval processes.
Disqualifier and next demonstration: An unsupported application type or unavailable mandatory output stops acceptance. Ask for the exact workflow in the current product and retain the report/output, not a roadmap assurance.
An existing v3.2.2 application with an incumbent publisher
Situation: The sponsor has an ongoing v3.2.2 application and a functioning publishing partner. Its recurring problem is sending the wrong source revision or an incomplete content plan.
Required output: A controlled handoff and an inspectable record of which versions were sent and filed.
Choice: Retain the incumbent publisher initially. Evaluate a content-and-handoff workflow such as Kivo, or the appropriate document/submission application in a broader suite. If replacing publishing itself, evaluate the exact LORENZ, EXTEDO, or other publishing configuration against the existing history.
Disqualifier and next demonstration: Assyro is excluded as the v3.2.2 publisher today. A replacement must demonstrate the needed legacy lifecycle; a viewer alone does not pass. Test one revised source through handoff and return of the published record.
Registrations and correspondence across several markets
Situation: A company cannot reliably join registration status, authority correspondence, and the owner of the next commitment. Its publisher already produces the dossiers.
Required output: A linked registration, letter, commitment, accountable owner, and status report.
Choice: Evaluate Veeva RIM, LifeSphere Regulatory, SmartSolve RIM, or Ennov RIM for the specified records and relationships. Retain the publisher unless a separate evaluation supports replacing it. Assyro's submission capability alone does not establish fit for this requirement.
Disqualifier and next demonstration: A dashboard without traceable underlying records fails. Seed one commitment with a missing owner: the system should expose the gap, not imply completion. For executive reporting, preserve the evidence through the submission-status-to-board-slides workflow.
The FDA format gate: match the application, not the slogan
FDA currently supports eCTD v4.0 for new NDA, BLA, ANDA, IND, and master-file applications, with support beginning September 16, 2024. Its notice says forward compatibility is not yet available and lists both v3.2.2 and v4.0 as supported versions. This is operational support for eligible new applications, not merely a sample-testing program. See the current FDA eCTD notice.
A tool supporting only the format required for your defined workflow can be eligible. You do not universally need every purchased tool to publish both formats. Conversely, “v4-ready” does not establish that an existing v3.2.2 application can move to v4.0 now. Record application status, authority, format, and required operation before evaluating the eCTD 4.0 vendor landscape.
Copy this buyer decision worksheet
Complete one record for each candidate configuration, including services and retained systems. These proposed procurement criteria are not a regulator-mandated checklist.
| Gate | Evidence to request | Accountable buyer |
|---|---|---|
| Intended use | Product type, markets, application history, required operation, and output | Regulatory lead |
| Present eligibility | Named edition/build, authority/format support, licensed modules | Regulatory operations |
| Data and history | Import sample with document versions, relationships, and open items reconciled | Data/process owner |
| Workflow control | Demonstration of approved versus draft content and unresolved exceptions | Process owner and QA |
| Handoff and ownership | Inspectable export, publisher/service responsibilities, retained final records | Regulatory operations |
| Supplier and system assurance | Evidence QA and IT need for the defined intended use and configuration | QA and IT |
| Commercial scope | Quote separating licenses, setup, migration, support, services, and exit terms | Procurement |
For each row record Pass, Fail, Unknown, or Not applicable, plus an evidence locator, reviewer, owner, and next action. A documented unmet mandatory requirement is Fail. Uninspected evidence is Unknown. Not applicable needs a reason and approval from the requirement owner. Do not compensate for a mandatory failure with a high usability score.
Completed example: The legacy-application buyer records “v3.2.2 publishing required; Assyro current scope excludes v3.2.2; Fail; owner: regulatory operations; action: retain incumbent publisher.” That decision does not depend on Assyro's editorial position in this article.
Unknown example: A RIM candidate demonstrates a registration dashboard but has not imported historical letters. Record migration/history as Unknown, assign the data owner to supply a permitted sample, and require reconciliation before deciding. A planned migration service is not the acceptance result.
After mandatory gates pass, choose preferences that match the team's work: reviewer effort, administration, handoff frequency, implementation capacity, and total cost. Use the vendor-selection framework for procurement structure, but set your own priorities rather than adopting universal percentage weights.
Request year-one and ongoing costs separately. Count retained systems and service fees once, including the internal work of cleaning data, reviewing outputs, and maintaining the process. When comparing services with software, keep the deliverable and sponsor responsibilities constant; a software license and an operated submission service are different scopes.
Take the smallest complete workflow into evaluation
Choose one application, one controlled source, and one required output. Include an ordinary successful case, a wrong or unapproved record, and an unresolved item. This gives the team something concrete to review before expanding to its full portfolio.
Use the submission-tracking guide when ownership and dates are the gap, and the validation comparison when you need to distinguish technical reports from content review. Passing one set of checks does not establish that all other work is complete.
For an eligible FDA v4.0 use case, book an Assyro demo with the completed intended-use row and a permitted sample. Ask which steps are available today, which systems remain involved, and what evidence you can retain. The next purchase decision should follow the demonstrated workflow and its limits.
About the author
Assyro Team
Expert regulatory operations consultants helping pharmaceutical companies navigate complex compliance challenges.

